About: Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis
Creator	Barnes, Geoffrey Cushman, Mary Diaz, Jose Faha, Peter, \| Creager, Mark Machlus, Kellie Wolberg, Alisa Henke, K Marvin, \| Nieman, T
Source	Medline; PMC
abstract	Venous thromboembolism (VTE) is a major cause of morbidity and mortality. The impact of the Surgeon General’s Call to Action in 2008 has been lower than expected given the public health impact of this disease. This scientific statement highlights future research priorities in VTE, developed by experts and a crowdsourcing survey across 16 scientific organizations. At the fundamental research level (T0), researchers need to identify pathobiologic causative mechanisms for the 50% of patients with unprovoked VTE and better understand mechanisms that differentiate hemostasis from thrombosis. At the human level (T1), new methods for diagnosing, treating, and preventing VTE will allow tailoring of diagnostic and therapeutic approaches to individuals. At the patient level (T2), research efforts are required to understand how foundational evidence impacts care of patients (eg, biomarkers). New treatments, such as catheter‐based therapies, require further testing to identify which patients are most likely to experience benefit. At the practice level (T3), translating evidence into practice remains challenging. Areas of overuse and underuse will require evidence‐based tools to improve care delivery. At the community and population level (T4), public awareness campaigns need thorough impact assessment. Large population‐based cohort studies can elucidate the biologic and environmental underpinings of VTE and its complications. To achieve these goals, funding agencies and training programs must support a new generation of scientists and clinicians who work in multidisciplinary teams to solve the pressing public health problem of VTE.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1002/rth2.12373
bibo:pmid	32685877
has license	cc-by-nc-nd
sha1sum (hex)	7b2e0aa0ee3e048ca794cd583aca96974a1f4697
schema:url	https://doi.org/10.1002/rth2.12373
resource representing a document's title	Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis
has PubMed Central identifier	PMC7354403
has PubMed identifier	32685877
schema:publication	Res Pract Thromb Haemost
resource representing a document's body	covid:7b2e0aa0ee3e048ca794cd583aca96974a1f4697#body_text
is schema:about of	named entity 'original' named entity 'Vascular' named entity 'International Society' named entity 'cited' named entity 'coagulopathy' named entity 'hemostasis' named entity 'VTE' named entity 'genetic analysis' named entity 'International Society' named entity 'original work' named entity 'American Heart Association' named entity 'Peripheral Vascular Disease' named entity 'Arteriosclerosis, Thrombosis, and Vascular Biology' named entity 'animal research' named entity 'diagnostic accuracy' named entity 'translational research' named entity 'VTE' named entity 'venous thromboembolism' named entity 'long-term' named entity 'VTE' named entity 'biochemical' named entity 'translational research' named entity 'public health' named entity 'surgeon' named entity 'thrombus' named entity 'VTE' named entity 'VTE' named entity 'thrombosis' named entity 'vessel wall' named entity 'quality of life' named entity 'hemostasis' named entity 'animal models' named entity 'care delivery' named entity 'embolic' named entity 'animal models' named entity 'embolic' named entity 'older adults' named entity 'evidence base' named entity 'thrombosis' named entity 'VTE' named entity 'High-quality' named entity 'public health' named entity 'big data' named entity 'VTE' named entity 'thrombosis' named entity 'venous thromboembolism' named entity 'VTE' named entity 'prophylaxis' named entity 'health services' named entity 'VTE' named entity 'embolic' named entity 'diagnostic testing' named entity 'pathobiology' named entity 'epigenetic factors' named entity 'evidence-based practices' named entity 'natural language processing' named entity 'biochemical studies' named entity 'anticoagulant' named entity 'evidence-based' named entity 'blood flow' named entity 'VTE' named entity 'prophylaxis' named entity '1 million' named entity 'therapeutic benefits' named entity 'VTE' named entity 'thrombosis' named entity 'VTE' named entity 'Multidisciplinary teams' named entity 'translational research' named entity 'autoimmune diseases' named entity 'blood components'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software